Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.
Trend Table & Recent Alerts
|Weak or Absent||Down||Down||Up|
|See historical ACRX trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 13||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Jan 13||Bollinger Band Squeeze||Range Contraction||0.00%|
|Jan 13||50 DMA Resistance||Bearish||0.00%|
|Jan 12||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Jan 12||Bollinger Band Squeeze||Range Contraction||0.00%|
|Jan 11||Volume Surge||Other||5.56%|
|Jan 11||50 DMA Resistance||Bearish||5.56%|
|Jan 10||Doji - Bearish?||Reversal||7.55%|
|Jan 6||New Downtrend||Bearish||9.62%|
|Jan 5||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||7.55%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The companys principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physicians office. In addition, the companys product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACRX news...
|52 Week High||4.5|
|52 Week Low||2.4|
|200-Day Moving Average||3.2|
|50-Day Moving Average||2.89|
|20-Day Moving Average||2.73|
|10-Day Moving Average||2.67|
|Average True Range||0.18|
|Chandelier Exit (Long, 3 ATRs)||2.56|
|Chandelier Exit (Short, 3 ATRs)||2.99|
|Upper Bollinger Band||2.94|
|Lower Bollinger Band||2.52|
|Percent B (%b)||0.79|